Rubicon Research

RUBICON

Q: How strong is Rubicon Research balance sheet?

Balance sheet of Rubicon Research is strong.But short term working capital might become an issue for this company.

Q: Is the debt of Rubicon Research increasing or decreasing?

The net debt of Rubicon Research is decreasing.Latest net debt of Rubicon Research is ₹161 Crs as of Mar-25.This is less than Mar-24 when it was ₹284 Crs.

Q: Is Rubicon Research stock expensive?

There is insufficient historical data to gauge this.Latest PE of Rubicon Research is 75.83

Price

Small Cap

₹10,776 Cr.

New to Zerodha? Sign-up for free.

Rubicon Research, established in 1999, is a pharmaceutical company focused on R&D-driven, differentiated formulations for regulated markets, mainly the US. It has a strong portfolio of approved and commercialised products, with several in development and a global reach.

Rubicon Research, established in 1999, is a pharmaceutical company focused on R&D-driven, different… More

Low

570

52W Range

High

663

80.2

Sector PE

27.11

P/B

19.92

Div.Yield

ROE

24.84%

EBIDTA

ROCE

34.85

EPS

New to Zerodha? Sign-up for free.

Share Price
Financials
Revenue mix
Shareholdings
Peers
Forensics

This data is currently unavailable for this company.

Summary
Profit & Loss
Balance sheet
Cashflow

View Detailed Summary

This data is currently unavailable for this company.

Yearly | Quarterly

(In Cr.)

(In Cr.)
This data is currently unavailable for this company.

Financial Ratio's

(In %)

Detailed P&L Report

(In Cr.)

Detailed Balance Sheet

Financial Year (In Cr.)

Detailed Cash Flow

Product wise
Location wise

RUBICON
Revenue Mix

Latest

Historic

This data is currently unavailable for this company.

RUBICON
Revenue Mix

Latest

Historic

This data is currently unavailable for this company.

More Info

Shareholdings

Holders

Detailed Shareholdings

This data is currently unavailable for this company.

Peers

Detailed Peers

Forensics

View Detailed Forensics

Recent events

News
Corporate Actions

India's Rubicon Research rises as Motial Oswal begins coverage with 'buy'

Oct 31, 2025

This data is currently unavailable for this company.

More Small Cap Ideas

See similar 'Small' cap companies with recent activity

Promoter Buying

Companies where the promoters are bullish

Detailed List

Capex

Companies investing on expansion

Detailed List

Superstar Investor

Companies where well known investors have invested

Detailed List

Popular questions

Business
Financials
Share Price
Shareholdings

What does Rubicon Research do?

Rubicon Research is an integrated pharmaceutical company with business encompassing the entire value chain in the research, development and production of pharmaceutical products. Further, the company has robust sales and distribution capabilities in the US.

Who are the competitors of Rubicon Research?

Rubicon Research major competitors are Sun Pharma Inds., Aurobindo Pharma, Zydus Lifesciences, Strides Pharma Scien, Dr. Reddy's Lab, Alembic Pharma, Lupin. Market Cap of Rubicon Research is ₹10,188 Crs. While the median market cap of its peers are ₹89,720 Crs.

Is Rubicon Research financially stable compared to its competitors?

Rubicon Research seems to be financially stable compared to its competitors. The probability of it going bankrupt or facing a financial crunch seem to be lower than its immediate competitors.

Does Rubicon Research pay decent dividends?

The company seems to be paying a very low dividend. Investors need to see where the company is allocating its profits. Rubicon Research latest dividend payout ratio is 0.02% and 3yr average dividend payout ratio is 0.03%

How has Rubicon Research allocated its funds?

Companies resources are allocated to majorly unproductive assets like Inventory

How strong is Rubicon Research balance sheet?

Balance sheet of Rubicon Research is strong. But short term working capital might become an issue for this company.

Is the profitablity of Rubicon Research improving?

Yes, profit is increasing. The profit of Rubicon Research is ₹134 Crs for Mar 2025, ₹91.01 Crs for Mar 2024 and -₹16.89 Crs for Mar 2023

Is the debt of Rubicon Research increasing or decreasing?

The net debt of Rubicon Research is decreasing. Latest net debt of Rubicon Research is ₹161 Crs as of Mar-25. This is less than Mar-24 when it was ₹284 Crs.

Is Rubicon Research stock expensive?

There is insufficient historical data to gauge this. Latest PE of Rubicon Research is 75.83

Has the share price of Rubicon Research grown faster than its competition?

There is not enough historical data for the companies share price.

Is the promoter bullish about Rubicon Research?

There is Insufficient data to gauge this.

Are mutual funds buying/selling Rubicon Research?

There is Insufficient data to gauge this.

RUBICON

Share Price

Financials

Revenue mix

Shareholdings

Peers

Forensics

Summary

Profit & Loss

Balance sheet

Cashflow

Product wise

Location wise

Recent events

News

Corporate Actions

India's Rubicon Research rises as Motial Oswal begins coverage with 'buy'

More Small Cap Ideas

Promoter Buying

Capex

Superstar Investor

Popular questions

Business

Financials

Share Price

Shareholdings

What does Rubicon Research do?

Who are the competitors of Rubicon Research?

Is Rubicon Research financially stable compared to its competitors?

Does Rubicon Research pay decent dividends?

How has Rubicon Research allocated its funds?

How strong is Rubicon Research balance sheet?

Is the profitablity of Rubicon Research improving?

Is the debt of Rubicon Research increasing or decreasing?

Is Rubicon Research stock expensive?

Has the share price of Rubicon Research grown faster than its competition?

Is the promoter bullish about Rubicon Research?

Are mutual funds buying/selling Rubicon Research?